Skip to main content
. Author manuscript; available in PMC: 2016 Mar 16.
Published in final edited form as: Cell Metab. 2009 Feb;9(2):140–151. doi: 10.1016/j.cmet.2008.12.005

Figure 5. Rescue of diabetes and its secondary consequences in Pdx-DTG mice treated with sulfonylureas.

Figure 5

(A) Fed blood glucose levels from Pdx-DTG treated with glibenclamide pre- and post-tamoxifen induction respect to controls (WT- glibenclamide treated and Pdx-DTG untreated mice). At 6 weeks of age, Pdx-DTG mice were implanted with slow-release glibenclamide pellets 1-day before (black diamonds) or following onset of tamoxifen induction (grey diamonds) (n = 4 mice in each group). Dashed line shows response of WT mice to glibenclamide implantation (from Remedi and Nichols, 2008) (B) Insulin content of isolated islets from glibenclamide treated WT and Pdx-DTG mice 60 days after tamoxifen induction (mean ± s.e.m., n= 4 animals in each group). (C) Glucose-dependent insulin secretion from isolated islets. Batches of 10 islets were statically pre-incubated with low glucose and then incubated at different glucose concentrations (with or without glibenclamide or K+) for 1 hour. Released insulin was measured by radioimmunoassay. n=3 mice in each group, samples done in triplicates, in Pdx-DTG animals, implanted with glibenclamide pellets (before (pre-) or after (post-) induction, or control littermates. Significant differences *p<0.01 between test and 1 mM glucose control are indicated.